

Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients

20 November 2017

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of the FLAURA trial presented at the ESMO Asia 2017 Congress, simultaneously published in *The New England Journal of Medicine*.

EGFR mutations occur in 30-40% of NSCLC in Asian populations compared to 10-15% in Western populations. The phase III FLAURA trial compared osimertinib, a third generation EGFR-tyrosine kinase inhibitor (TKI), to standard of care EGFR-TKIs (erlotinib or gefitinib) as first line therapy in NSCLC [patients](#) with EGFR mutations. A total of 556 patients from Asia, Europe, and North America were randomised 1:1 to treatment with osimertinib or standard of care. Osimertinib improved progression-free survival by 54%.

This subset analysis included the 322 Asian patients in the FLAURA trial, of whom 46 were Chinese, 120 were Japanese, and 156 were from other parts of Asia.

The median progression-free survival was 16.5 months with osimertinib compared to 11.0 months for the standard [therapy](#), with a hazard ratio of 0.54 (95% confidence interval, 0.41-0.72; p

APA citation: Osimertinib improves progression-free survival in Asian EGFR-mutated lung cancer patients (2017, November 20) retrieved 28 April 2021 from <https://medicalxpress.com/news/2017-11-osimertinib-progression-free-survival-asian-egfr-mutated.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.